CN111349016A - 一种贝曲西班中间体的合成方法 - Google Patents
一种贝曲西班中间体的合成方法 Download PDFInfo
- Publication number
- CN111349016A CN111349016A CN201811559536.1A CN201811559536A CN111349016A CN 111349016 A CN111349016 A CN 111349016A CN 201811559536 A CN201811559536 A CN 201811559536A CN 111349016 A CN111349016 A CN 111349016A
- Authority
- CN
- China
- Prior art keywords
- compound
- organic solvent
- combination
- reaction
- toluene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- XHOLNRLADUSQLD-UHFFFAOYSA-N betrixaban Chemical compound C=1C=C(Cl)C=NC=1NC(=O)C1=CC(OC)=CC=C1NC(=O)C1=CC=C(C(=N)N(C)C)C=C1 XHOLNRLADUSQLD-UHFFFAOYSA-N 0.000 title claims abstract description 7
- 229950011103 betrixaban Drugs 0.000 title claims abstract description 7
- 238000010189 synthetic method Methods 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 28
- 239000003960 organic solvent Substances 0.000 claims abstract description 18
- 238000000034 method Methods 0.000 claims abstract description 12
- LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 claims abstract description 9
- USEDMAWWQDFMFY-UHFFFAOYSA-N 4-cyanobenzoyl chloride Chemical compound ClC(=O)C1=CC=C(C#N)C=C1 USEDMAWWQDFMFY-UHFFFAOYSA-N 0.000 claims abstract description 8
- 239000003054 catalyst Substances 0.000 claims abstract description 7
- 229940126062 Compound A Drugs 0.000 claims abstract description 6
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 claims abstract description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 27
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 21
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 18
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 18
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 12
- 238000006243 chemical reaction Methods 0.000 claims description 11
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 9
- 238000000967 suction filtration Methods 0.000 claims description 9
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 7
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 claims description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 6
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 6
- MAXBVGJEFDMHNV-UHFFFAOYSA-N 5-chloropyridin-2-amine Chemical compound NC1=CC=C(Cl)C=N1 MAXBVGJEFDMHNV-UHFFFAOYSA-N 0.000 claims description 5
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 claims description 5
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 4
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 claims description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 4
- 239000012065 filter cake Substances 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 4
- 238000005406 washing Methods 0.000 claims description 4
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 claims description 3
- 229910052739 hydrogen Inorganic materials 0.000 claims description 3
- 239000001257 hydrogen Substances 0.000 claims description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 3
- 239000012312 sodium hydride Substances 0.000 claims description 3
- 229910000104 sodium hydride Inorganic materials 0.000 claims description 3
- DSVGQVZAZSZEEX-UHFFFAOYSA-N [C].[Pt] Chemical compound [C].[Pt] DSVGQVZAZSZEEX-UHFFFAOYSA-N 0.000 claims description 2
- BRPQOXSCLDDYGP-UHFFFAOYSA-N calcium oxide Chemical compound [O-2].[Ca+2] BRPQOXSCLDDYGP-UHFFFAOYSA-N 0.000 claims description 2
- 239000000292 calcium oxide Substances 0.000 claims description 2
- ODINCKMPIJJUCX-UHFFFAOYSA-N calcium oxide Inorganic materials [Ca]=O ODINCKMPIJJUCX-UHFFFAOYSA-N 0.000 claims description 2
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- 229910052759 nickel Inorganic materials 0.000 claims description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 2
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 claims description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 2
- 238000001308 synthesis method Methods 0.000 claims description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 claims 2
- 238000001035 drying Methods 0.000 claims 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 1
- 238000005915 ammonolysis reaction Methods 0.000 abstract 1
- 239000003814 drug Substances 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 239000012074 organic phase Substances 0.000 description 3
- 238000001953 recrystallisation Methods 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 125000003277 amino group Chemical group 0.000 description 2
- 210000000941 bile Anatomy 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000007086 side reaction Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 229940123688 Direct Factor Xa inhibitor Drugs 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010062237 Renal impairment Diseases 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 208000001435 Thromboembolism Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C227/04—Formation of amino groups in compounds containing carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C253/00—Preparation of carboxylic acid nitriles
- C07C253/30—Preparation of carboxylic acid nitriles by reactions not involving the formation of cyano groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pyridine Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Abstract
本发明公开了一种简单、安全、高收率制备贝曲西班中间体的方法,其特征在于化合物A溶于有机溶剂在催化剂条件下氢化还原为化合物B,化合物B与4‑氰基苯甲酰氯反应生成化合物C,化合物C经氨解制备化合物D。
Description
技术领域
本发明属于医药技术领域,涉及一种凝血酶Xa因子抑制剂贝曲西班中间体的制备方法。
背景技术
贝曲西班,由默克与Protola公司研发的一种具有高选择性的直接Xa因子抑制剂,2012年3月作为脑卒中及血栓栓塞治疗药在美国、加拿大等30多个国家和地区进行III期临床研究,2013年扩展到中国。它的半衰期为20h,达峰时间3~4h,80mg(1次/d)的生物利用度为34%,血浆蛋白结合率达60%。大部分以原形通过胆汁排泄,仅17%通过肾脏代谢。它是目前唯一肾排泄最少的药物,主要以原型由胆汁排泄,可用于严重肾功能损害的病人。
专利CN1272316C报道了其合成方法:
该路线的缺点:第三步骤反应中4-氰基苯甲酰氯可与两个不同的氨基进行反应,从而产生副反应,造成收率降低,增加成本。
发明内容
本发明的目的是为克服上述现有技术的不足,提供一种简便安全、中间体质量可控的制备贝曲西班中间体的方法。
为实现上述目的,本发明采用下述技术方案:
包括以下三个步骤:
步骤一:将化合物A溶于有机溶剂a中(化合物A与有机溶剂a的质量体积比W/V=0.5—0.02),加入催化剂a,通入氢气,10--100℃,0.1—2MPa反应。反应结束后,抽滤,有机溶剂a用饱和食盐水洗涤,分液,有机相用无水硫酸钠干燥,浓缩,重结晶,得化合物B。
步骤二:将化合物B溶于有机溶剂b中(化合物B与有机溶剂b的质量体积比W/V=1—0.02),加入4-氰基苯甲酰氯,-20--100℃反应。反应结束后,抽滤,有机溶剂b用饱和食盐水洗涤,分液,有机相用无水硫酸钠干燥,浓缩,重结晶,得化合物C。
步骤三:将化合物C溶于有机溶剂c中(化合物C与有机溶剂c的质量体积比W/V=1—0.03),加入2-氨基-5-氯吡啶和碱性介质a,-20--130℃反应。反应结束后抽滤,洗涤滤饼,得化合物D。
其中,化合物A与催化剂a的物质的量之比为1:0.005--0.1;化合物B与4-氰基苯甲酰氯的物质的量之比为1:1--4;化合物C,2-氨基-5-氯吡啶与碱性介质a的物质的量之比为1:1—4:1—4。
所述步骤一中化合物A的R基团为苯基、甲基。
所述步骤一中的有机溶剂a为二氯甲烷、四氢呋喃、乙腈、甲苯、乙酸乙酯、异丙醚中的任一种或任其组合。
所述步骤一中的催化剂a为镍、钯碳、铂碳中任一种或任其组合。
所述步骤二中的有机溶剂b为四氢呋喃、吡啶、二氯甲烷、乙酸乙酯、乙腈、甲苯、甲基叔丁基醚、异丙醚、N,N-二甲基甲酰胺中的任一种或其任意组合。
所述步骤三中的有机溶剂c为甲醇、乙醇、异丙醇、甲苯、乙腈、N,N-二甲基甲酰胺、二氯甲烷、乙酸乙酯、甲基叔丁基醚、异丙醚、四氢呋喃中的任一种或其任意组合。
所述步骤三中的碱性介质a为氧化钙、碳酸钾、碳酸钠、氢氧化钾、氢氧化钠、氢化钠、叔丁醇钾、三乙胺或N,N-二甲基甲酰胺中的任一种或其任意组合。
本发明的有益效果:步骤二中化合物B中只有一个氨基,无副反应,可得较高收率。该路线所涉及的化合物为全新化合物,该反应路线总收率较其他报道路线高,有利于工业化生产。
具体实施方式
下面结合实施例对本发明进行进一步的阐述,应该说明的是,下述说明仅是为了解释本发明,并不对其内容进行限定。
实施例1:化合物B1的制备
化合物A1(50g,0.183mol)溶于二氯甲烷(750ml),加入5%铂/碳(硫化,0.50g),搅拌,用约0.2MPa氢气加压反应器,将反应体系缓慢升温至35℃。15小时后,HPLC监控反应至原料小于0.1%。抽滤,用250ml饱和食盐水洗涤滤液,分液,用无水硫酸钠(5g)干燥有机相。抽滤,浓缩,得棕色油状物,用150ml乙醇重结晶,抽滤,用20ml冷乙醇洗涤滤饼。得40.1g类白色固体(化合物B1),纯度99.46%,收率90.1%。化合物B1核磁共振数据见附录。
实施例2:化合物C1的制备:
4-氰基苯甲酰氯(30.0g,0.18mol)溶于150mlTHF,待用,将化合物B1(40.0g,0.16mol),溶于600molTHF和16ml吡啶。冰浴,控温0-10℃,将4-氰基苯甲酰氯溶液缓慢滴加至体系中。室温搅拌3小时,HPLC监控反应至原料含量为0%,指示反应完成。抽滤,浓缩,得黄色油状物,用100ml乙醇重结晶,得白色固体(化合物C1)54.2g,纯度98.8%,收率88.5%。化合物C1核磁共振数据见附录。
实施例3:
化合物D的制备:
-15℃下,2-氨基-5-氯吡啶(17.3g,0.134mol)溶于400ml甲苯,加入60%氢化钠(8.1g,0.202mol),搅拌2小时,滴加化合物C1(50.0g,0.134mol)的甲苯溶液(200ml),1小时滴加完毕。反应混合物90℃搅拌10小时,HPLC监控反应至原料小于0.1%。降温至0℃,加入150ml水,25℃搅拌3小时。抽滤,用50ml甲苯洗涤滤饼,得白色固体(化合物D)46.5g,收率85.4%。
Claims (10)
2.根据权利要求1所述的制备方法,其特征在于,步骤一中所述的化合物A与催化剂a的物质的量之比为1:0.005--0.1。
3.根据权利要求1的制备方法,其特征在于,步骤一中所述化合物A的R基团为苯基、甲基。
4.根据权利要求1的制备方法,其特征在于,步骤一中所述的有机溶剂a为二氯甲烷、四氢呋喃、乙腈、甲苯、乙酸乙酯、异丙醚中的任一种或任其组合。
5.根据权利要求1的制备方法,其特征在于,步骤一中所述的催化剂a为镍、钯碳、铂碳中任一种或任其组合。
6.根据权利要求1所述的制备方法,其特征在于,步骤二中所述的化合物B与4-氰基苯甲酰氯的物质的量之比为1:1—4。
7.根据权利要求1所述的制备方法,其特征在于,步骤二中所述的有机溶剂b为四氢呋喃、吡啶、二氯甲烷、乙酸乙酯、乙腈、甲苯、甲基叔丁基醚、异丙醚、N,N-二甲基甲酰胺中的任一种或其任意组合。
8.根据权利要求1所述的制备方法,其特征在于,步骤三中所述的化合物C,2-氨基-5-氯吡啶与碱性介质a的物质的量之比为1:1—4:1—4。
9.根据权利要求1所述的制备方法,其特征在于,步骤三中所述的有机溶剂c为甲醇、乙醇、异丙醇、甲苯、乙腈、N,N-二甲基甲酰胺、二氯甲烷、乙酸乙酯、甲基叔丁基醚、异丙醚、四氢呋喃中的任一种或其任意组合。
10.根据权利要求1所述的制备方法,其特征在于,步骤三中所述的碱性介质a为氧化钙、碳酸钾、碳酸钠、氢氧化钾、氢氧化钠、氢化钠、叔丁醇钾、三乙胺或N,N-二异丙基乙基胺中的任一种或其任意组合。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811559536.1A CN111349016A (zh) | 2018-12-20 | 2018-12-20 | 一种贝曲西班中间体的合成方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811559536.1A CN111349016A (zh) | 2018-12-20 | 2018-12-20 | 一种贝曲西班中间体的合成方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN111349016A true CN111349016A (zh) | 2020-06-30 |
Family
ID=71190026
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201811559536.1A Pending CN111349016A (zh) | 2018-12-20 | 2018-12-20 | 一种贝曲西班中间体的合成方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111349016A (zh) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101166712A (zh) * | 2005-04-29 | 2008-04-23 | 株式会社太平洋 | 异羟肟酸衍生物及其制备方法 |
CN102333757A (zh) * | 2009-01-30 | 2012-01-25 | 富山化学工业株式会社 | N-酰基邻氨基苯甲酸衍生物或其盐 |
CN106518758A (zh) * | 2015-09-11 | 2017-03-22 | 扬子江药业集团江苏紫龙药业有限公司 | 贝曲西班中间体n-(5-氯-2-吡啶基)-2-(4-氰基苯甲酰胺基)-5-甲氧基苯甲酰胺的制备方法 |
-
2018
- 2018-12-20 CN CN201811559536.1A patent/CN111349016A/zh active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101166712A (zh) * | 2005-04-29 | 2008-04-23 | 株式会社太平洋 | 异羟肟酸衍生物及其制备方法 |
CN102333757A (zh) * | 2009-01-30 | 2012-01-25 | 富山化学工业株式会社 | N-酰基邻氨基苯甲酸衍生物或其盐 |
CN106518758A (zh) * | 2015-09-11 | 2017-03-22 | 扬子江药业集团江苏紫龙药业有限公司 | 贝曲西班中间体n-(5-氯-2-吡啶基)-2-(4-氰基苯甲酰胺基)-5-甲氧基苯甲酰胺的制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3828170A1 (en) | Method for safely preparing pimavanserin and tartrate salt thereof using triphosgene | |
CN100588646C (zh) | 3-氨基-2,2-双甲基丙酰胺的工业化制备方法 | |
CN112375117A (zh) | 石胆酸及其中间体的制备方法 | |
CN104356092A (zh) | 沃替西汀的制备方法 | |
CN102351778A (zh) | 一种盐酸阿比朵尔的制备方法 | |
CN104860923A (zh) | 富马酸沃诺拉赞的制备方法 | |
CN111349016A (zh) | 一种贝曲西班中间体的合成方法 | |
CN111320548A (zh) | 抗癌药物中间体2-氟-3-氨基苯甲酸甲酯的合成方法 | |
CN110922409A (zh) | 制备btk抑制剂泽布替尼的方法 | |
CN112939814B (zh) | 一种氘代达卡他韦中间体的制备方法 | |
CN113336761B (zh) | 一种jak抑制剂关键中间体的制备方法 | |
CN113480481B (zh) | 一种盐酸伊伐布雷定中降解杂质的制备方法 | |
WO2023039940A1 (zh) | 一种制备n,n,n-三特戊酰化-1,3,5-三氨基苯的方法 | |
CN102964336B (zh) | 质子泵抑制剂的精制方法及其n-氧化物的还原方法 | |
CN105884746B (zh) | 氟马替尼的合成方法 | |
CN109400504A (zh) | Lcz696中间体非对映异构体的分离纯化方法 | |
CN106518939B (zh) | 一种制备Solithromycin化合物的方法 | |
CN109824539B (zh) | 一种由去甲基金霉素合成替加环素的新方法 | |
CN108610308A (zh) | 一锅法制备尼达尼布中间体的方法 | |
CN108409648B (zh) | 一种甲苯磺酸索拉非尼相关中间体的制备方法 | |
AU2021297767A1 (en) | Preparation method for aromatic ether compound | |
CN108299466B (zh) | 一种改进的度鲁特韦合成方法 | |
CN112341347A (zh) | 一种盐酸氨溴索的合成方法 | |
CN101088999A (zh) | 3-氨基奎宁二盐酸盐的合成方法 | |
CN104761548A (zh) | 一种稳定同位素标记的二苯基磺酰胺类药物的制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20200630 |